Loading...

Genetic Signatures

ASX:GSS
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GSS
ASX
A$128M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Genetic Signatures Limited operates as a molecular diagnostic company in North America and Australia. The last earnings update was 146 days ago. More info.


Add to Portfolio Compare Print
GSS Share Price and Events
7 Day Returns
13.9%
ASX:GSS
6.5%
AU Life Sciences
0%
AU Market
1 Year Returns
223.7%
ASX:GSS
-5.7%
AU Life Sciences
4.8%
AU Market
GSS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Genetic Signatures (GSS) 13.9% 15% 3.4% 223.7% 146% -
AU Life Sciences 6.5% 11.3% 1.8% -5.7% -41.4% -88.8%
AU Market 0% 0.9% 6.8% 4.8% 20.1% 12.2%
1 Year Return vs Industry and Market
  • GSS outperformed the Life Sciences industry which returned -5.7% over the past year.
  • GSS outperformed the Market in Australia which returned 4.8% over the past year.
Price Volatility
GSS
Industry
5yr Volatility vs Market

GSS Value

 Is Genetic Signatures undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Genetic Signatures. This is due to cash flow or dividend data being unavailable. The share price is A$1.23.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Genetic Signatures's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Genetic Signatures's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:GSS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$-0.03
ASX:GSS Share Price ** ASX (2019-07-19) in AUD A$1.23
Global Life Sciences Industry PE Ratio Median Figure of 53 Publicly-Listed Life Sciences Companies 38.51x
Australia Market PE Ratio Median Figure of 546 Publicly-Listed Companies 16.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Genetic Signatures.

ASX:GSS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:GSS Share Price ÷ EPS (both in AUD)

= 1.23 ÷ -0.03

-38.71x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genetic Signatures is loss making, we can't compare its value to the Global Life Sciences industry average.
  • Genetic Signatures is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Genetic Signatures's expected growth come at a high price?
Raw Data
ASX:GSS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -38.71x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Global Life Sciences Industry PEG Ratio Median Figure of 38 Publicly-Listed Life Sciences Companies 2.61x
Australia Market PEG Ratio Median Figure of 361 Publicly-Listed Companies 1.38x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Genetic Signatures, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Genetic Signatures's assets?
Raw Data
ASX:GSS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.11
ASX:GSS Share Price * ASX (2019-07-19) in AUD A$1.23
Australia Life Sciences Industry PB Ratio Median Figure of 9 Publicly-Listed Life Sciences Companies 5.26x
Australia Market PB Ratio Median Figure of 1,693 Publicly-Listed Companies 1.7x
ASX:GSS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:GSS Share Price ÷ Book Value per Share (both in AUD)

= 1.23 ÷ 0.11

10.77x

* Primary Listing of Genetic Signatures.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genetic Signatures is overvalued based on assets compared to the AU Life Sciences industry average.
X
Value checks
We assess Genetic Signatures's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Genetic Signatures has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

GSS Future Performance

 How is Genetic Signatures expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Genetic Signatures has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
16.4%
Expected Life Sciences industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Genetic Signatures expected to grow at an attractive rate?
  • Unable to compare Genetic Signatures's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Genetic Signatures's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Genetic Signatures's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:GSS Future Growth Rates Data Sources
Data Point Source Value (per year)
Global Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 16.4%
Global Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 8.2%
Australia Market Earnings Growth Rate Market Cap Weighted Average 7.4%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:GSS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:GSS Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 6 -2 -3
2018-09-30 5 -3 -3
2018-06-30 5 -4 -3
2018-03-31 5 -3 -3
2017-12-31 5 -3 -3
2017-09-30 4 -3 -3
2017-06-30 4 -3 -3
2017-03-31 4 -2 -3
2016-12-31 4 -2 -3
2016-09-30 3 -2 -3
2016-06-30 3 -3 -3
2016-03-31 3 -3 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Genetic Signatures is high growth as no earnings estimate data is available.
  • Unable to determine if Genetic Signatures is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:GSS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Genetic Signatures Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:GSS Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 -0.03
2018-09-30 -0.03
2018-06-30 -0.03
2018-03-31 -0.03
2017-12-31 -0.03
2017-09-30 -0.03
2017-06-30 -0.03
2017-03-31 -0.03
2016-12-31 -0.03
2016-09-30 -0.04
2016-06-30 -0.04
2016-03-31 -0.04

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Genetic Signatures will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Genetic Signatures's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Genetic Signatures's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Genetic Signatures's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Genetic Signatures's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Global market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Global market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Genetic Signatures has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

GSS Past Performance

  How has Genetic Signatures performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Genetic Signatures's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Genetic Signatures does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Genetic Signatures's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Genetic Signatures's 1-year growth to the Global Life Sciences industry average as it is not currently profitable.
Earnings and Revenue History
Genetic Signatures's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Genetic Signatures Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:GSS Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 5.99 -3.30 5.30
2018-09-30 5.49 -3.28 5.06
2018-06-30 4.99 -3.25 4.81
2018-03-31 4.79 -3.14 4.62
2017-12-31 4.59 -3.03 4.44
2017-09-30 4.33 -2.85 4.17
2017-06-30 4.06 -2.67 3.91
2017-03-31 3.88 -2.71 4.00
2016-12-31 3.69 -2.75 4.08
2016-09-30 3.48 -2.89 4.14
2016-06-30 3.27 -3.03 4.21
2016-03-31 2.97 -2.97 3.84
2015-12-31 2.67 -2.91 3.47
2015-09-30 2.34 -2.79 3.00
2015-06-30 2.01 -2.66 2.53
2014-06-30 1.29 -1.73 1.50
2013-06-30 0.26 -2.01 1.64

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Genetic Signatures has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Genetic Signatures has efficiently used its assets last year compared to the Global Life Sciences industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Genetic Signatures improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Genetic Signatures's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Genetic Signatures has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

GSS Health

 How is Genetic Signatures's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Genetic Signatures's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Genetic Signatures is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Genetic Signatures's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Genetic Signatures's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Genetic Signatures has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Genetic Signatures Company Filings, last reported 6 months ago.

ASX:GSS Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 11.87 0.00 8.82
2018-09-30 11.87 0.00 8.82
2018-06-30 13.40 0.00 8.95
2018-03-31 13.40 0.00 8.95
2017-12-31 14.36 0.00 11.72
2017-09-30 14.36 0.00 11.72
2017-06-30 16.49 0.00 13.19
2017-03-31 16.49 0.00 13.19
2016-12-31 17.63 0.00 16.01
2016-09-30 17.63 0.00 16.01
2016-06-30 4.68 0.00 2.56
2016-03-31 4.68 0.00 2.56
2015-12-31 5.70 0.00 4.32
2015-09-30 5.70 0.00 4.32
2015-06-30 7.06 0.00 5.46
2014-06-30 2.61 0.00 1.85
2013-06-30 -3.32 3.92 0.15
  • Genetic Signatures has no debt.
  • Genetic Signatures currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Genetic Signatures has sufficient cash runway for more than 3 years based on current free cash flow.
  • Genetic Signatures has sufficient cash runway for 2.8 years if free cash flow continues to grow at historical rates of 8.3% each year.
X
Financial health checks
We assess Genetic Signatures's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Genetic Signatures has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

GSS Dividends

 What is Genetic Signatures's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Genetic Signatures dividends.
If you bought A$2,000 of Genetic Signatures shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Genetic Signatures's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Genetic Signatures's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:GSS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 23 Stocks 0.5%
Australia Market Average Dividend Yield Market Cap Weighted Average of 415 Stocks 4%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.4%
Australia Bottom 25% Dividend Yield 25th Percentile 2.5%
Australia Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Genetic Signatures has not reported any payouts.
  • Unable to verify if Genetic Signatures's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Genetic Signatures's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Genetic Signatures has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Genetic Signatures's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Genetic Signatures afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Genetic Signatures has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

GSS Management

 What is the CEO of Genetic Signatures's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
John Melki
COMPENSATION A$375,802
TENURE AS CEO 8.5 years
CEO Bio

Dr. John R. Melki, BSc, Ph.D. has been the Chief Executive Officer of Genetic Signatures Limited since 2011 and serves as its Managing Director and also served as its Senior Principal Research Scientist and Principal Advisor. Dr. Melki has been a Director of Genetic Signatures Limited since April 4, 2014. Dr. Melki has broad laboratory experience in the key areas of microarray technologies, Real-Time PCR, DNA methyltransferase expression studies, methylation analyses in acute myeloid leukemias and biological software evaluation. He worked at the Sydney Cancer Centre on the characterisation of methylation patterns in human cells using laser capture technology. Dr. Melki was awarded the Faculty of Medicine Peter Bancroft prize for best thesis in 2000. He holds a PhD in Molecular Biology from the University of Sydney.

CEO Compensation
  • John's compensation has been consistent with company performance over the past year, both up more than 20%.
  • John's remuneration is about average for companies of similar size in Australia.
Management Team Tenure

Average tenure of the Genetic Signatures management team in years:

5.5
Average Tenure
  • The average tenure for the Genetic Signatures management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

John Melki

TITLE
MD, CEO & Director
COMPENSATION
A$376K
TENURE
8.5 yrs

Doug Millar

TITLE
Chief Scientific Officer
COMPENSATION
A$309K
TENURE
18.5 yrs

Mike Aicher

TITLE
Executive Director of US Operations & Executive Director
COMPENSATION
A$163K
AGE
59
TENURE
5.5 yrs

Chris Abbott

TITLE
Founder & Chairman Emeritus

Peter Manley

TITLE
CFO & Company Secretary
TENURE
0.8 yrs

Pat Noland

TITLE
US Market Consultant
COMPENSATION
A$4K
TENURE
3 yrs
Board of Directors Tenure

Average tenure of the Genetic Signatures board of directors in years:

5.3
Average Tenure
  • The tenure for the Genetic Signatures board of directors is about average.
Board of Directors

Nick Samaras

TITLE
Independent Non-Executive Chairman
COMPENSATION
A$74K
TENURE
11.5 yrs

John Melki

TITLE
MD, CEO & Director
COMPENSATION
A$376K
TENURE
5.3 yrs

Mike Aicher

TITLE
Executive Director of US Operations & Executive Director
COMPENSATION
A$163K
AGE
59
TENURE
5.2 yrs

Chris Abbott

TITLE
Founder & Chairman Emeritus

Phillip Isaacs

TITLE
Independent Non-Executive Director
COMPENSATION
A$54K
TENURE
15.6 yrs

Tony Radford

TITLE
Independent Non-Executive Director
COMPENSATION
A$63K
AGE
62
TENURE
3.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
21. Mar 19 Sell Anthony Radford Individual 15. Mar 19 18. Mar 19 -107,000 A$1.16 A$-124,053
21. Nov 18 Buy Karst Peak Capital Limited Company 16. Nov 18 16. Nov 18 4,040,910 A$0.57 A$2,303,319
X
Management checks
We assess Genetic Signatures's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Genetic Signatures has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

GSS News

Simply Wall St News

Did You Miss Genetic Signatures's (ASX:GSS) Impressive 176% Share Price Gain?

See our latest analysis for Genetic Signatures Genetic Signatures isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … In the last year Genetic Signatures saw its revenue grow by 31%. … If you would like to research Genetic Signatures in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company.

Simply Wall St -

Is Genetic Signatures Limited's (ASX:GSS) CEO Pay Fair?

Check out our latest analysis for Genetic Signatures How Does John Melki's Compensation Compare With Similar Sized Companies? … Our data indicates that Genetic Signatures Limited is worth AU$112m, and total annual CEO compensation is AU$376k. … Boasting a total shareholder return of 111% over three years, Genetic Signatures Limited has done well by shareholders.

Simply Wall St -

How Much Are Genetic Signatures Limited (ASX:GSS) Insiders Taking Off The Table?

In the last twelve months, the biggest single sale by an insider was when the Independent Non-Executive Director, Anthony Radford, sold AU$124k worth of shares at a price of AU$1.16 per share. … So we know that an insider sold shares at around the present share price of AU$1.15. … While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price

Simply Wall St -

What Type Of Shareholder Owns Genetic Signatures Limited's (ASX:GSS)?

Every investor in Genetic Signatures Limited (ASX:GSS) should be aware of the most powerful shareholder groups. … Genetic Signatures is a smaller company with a market capitalization of AU$113m, so it may still be flying under the radar of many institutional investors. … View our latest analysis for Genetic Signatures

Simply Wall St -

Genetic Signatures Shareholders Have Enjoyed An Impressive 228% Share Price Gain

Genetic Signatures isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … Shareholders of unprofitable companies usually expect strong revenue growth. … That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

Simply Wall St -

Should You Worry About Genetic Signatures Limited's (ASX:GSS) CEO Pay Cheque?

In 2011 John Melki was appointed CEO of Genetic Signatures Limited (ASX:GSS). … This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does John Melki's Compensation Compare With Similar Sized Companies?

Simply Wall St -

What does Genetic Signatures Limited's (ASX:GSS) Balance Sheet Tell Us About Its Future?

The direct benefit for Genetic Signatures Limited (ASX:GSS), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … However, the trade-off is GSS will have to adhere to stricter debt covenants and have less financial flexibility. … Is GSS growing fast enough to value financial flexibility over lower cost of capital.

Simply Wall St -

What Kind Of Investor Owns Most Of Genetic Signatures Limited (ASX:GSS)?

Generally speaking, as a company grows, institutions will increase their ownership. … So it's nice to see some insider ownership, because it may suggest that management is owner-oriented. … Check out our latest analysis for Genetic Signatures

Simply Wall St -

How Much is Genetic Signatures Limited's (ASX:GSS) CEO Getting Paid?

John Melki became the CEO of Genetic Signatures Limited (ASX:GSS) in 2011. … How Does John Melki's Compensation Compare With Similar Sized Companies. … We examined a group of similar sized companies, with market capitalizations of below AU$282m.

Simply Wall St -

Genetic Signatures Limited (ASX:GSS): Does The Earnings Decline Make It An Underperformer?

In this commentary, I will examine Genetic Signatures Limited's (ASX:GSS) latest earnings update (31 December 2017) and compare these figures against its performance over the past couple of years, as well as how the rest of the life sciences industry performed. … View out our latest analysis for Genetic Signatures? … GSS is loss-making, with the most recent trailing twelve-month earnings of -AU$3.55m (from 31 December 2017), which compared to last year has become

Simply Wall St -

GSS Company Info

Description

Genetic Signatures Limited operates as a molecular diagnostic company in North America and Australia. The company designs and manufactures a suite of real-time polymerase chain reaction based products for detection of infectious diseases under EasyScreen brand name. It also provides MethylEasy for DNA bisulphite modification of histones for screening of cancer and embryonic development, as well as use in stem cell technologies. Genetic Signatures Limited was founded in 2001 and is headquartered in Newtown, Australia.

Details
Name: Genetic Signatures Limited
GSS
Exchange: ASX
Founded: 2001
A$127,958,052
104,030,937
Website: http://www.geneticsignatures.com
Address: Genetic Signatures Limited
7 Eliza Street,
Newtown,
New South Wales, 2042,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX GSS Ordinary Shares Australian Securities Exchange AU AUD 31. Mar 2015
CHIA GSS Ordinary Shares Chi-X Australia AU AUD 31. Mar 2015
Number of employees
Current staff
Staff numbers
0
Genetic Signatures employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/20 10:38
End of day share price update: 2019/07/19 00:00
Last earnings filing: 2019/02/24
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.